학술논문
Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial)
Document Type
Article
Author
Kroeger, Nicolaus; Iacobelli, Simona; Koster, Linda; Niederwieser, Dietger; Platzbecker, Uwe; Huebel, Kai; Scheid, Christoph; Weber, Thomas; Stelljes, Matthias; Afanasiev, Boris; Heim, Dominik; Lambertenghi Deliliers, Giorgio; Onida, Francesco; Dreger, Peter; Pini, Massimo; Guidi, Stefano; Volin, Liisa; Guenther, Andreas; Bethge, Wolfgang; Poire, Xavier; Kobbe, Guido; van Os, Marleen; Yakoub-Agha, Ibrahim; Robin, Marie
Source
Blood; November 2018, Vol. 132 Issue: Supplement 1 p1019-1019, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Niederwieser: Miltenyi: Speakers Bureau; Novartis: Research Funding. Platzbecker:Celgene: Research Funding. Scheid:Celgene: Honoraria; Janssen: Honoraria; Novartis: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; BMS: Honoraria; Amgen: Honoraria. Stelljes:MSD: Consultancy; Amgen: Honoraria; JAZZ: Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Novartis: Honoraria. Heim:Novartis: Research Funding. Bethge:Miltenyi Biotec GmbH: Consultancy, Honoraria, Research Funding; Neovii GmbH: Honoraria, Research Funding. Kobbe:Roche: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Celgene: Honoraria, Other: Travel Support, Research Funding.